Surgical debridement with retention of spinal instrumentation and long-term antimicrobial therapy for multidrug-resistant surgical site infections after spinal surgery: a case series
- 394 Downloads
Post-operative surgical site infection (SSI) is one of the most significant complications after instrumented spinal surgery. However, implant retention feasibility for early-onset multidrug-resistant SSI is still controversial. We aimed to verify our therapeutic strategy, surgical debridement with implant retention and long-term antimicrobial therapy for post-operative early-onset multidrug-resistant SSI.
We retrospectively analyzed the clinical course of 11 cases [eight men and three women, with a mean age of 70.4 (54–82) years] with early-onset multidrug-resistant SSI out of 409 consecutive cases of spinal instrumentation surgery performed between 2007 and 2013 at our institution.
The median duration of follow-up was 868 (178–1,922) days. All SSIs were controlled, without recurrence during follow-up. The microbial pathogens were methicillin-resistant Staphylococcus aureus (seven cases), multidrug-resistant Corynebacterium (two cases), methicillin-resistant Staphylococcus epidermidis (one case), and methicillin-resistant coagulase-negative Staphylococcus aureus (one case). The mean duration from SSI diagnosis to surgery was 2.9 (1–6) days. Ten patients underwent surgical debridement with implant retention. No patients required multiple operations. All patients were given antimicrobial treatments. Mean duration of intravenous antimicrobials (vancomycin, vancomycin+ piperacillin/tazobactam, or gentamicin) was 66.5 (12–352) days and 336 (89–1,673) days for oral antimicrobials (rifampicin + sulfamethoxazole/trimethoprim, sulfamethoxazole/trimethoprim, or minomycin). The mean duration of clinical signs and symptom recovery was 31.0 (7–73) days, and the mean time for normalization of C-reactive protein was 54.5 (7–105) days.
Early-onset multidrug-resistant SSI was successfully treated by surgical debridement with implant retention and long-term antimicrobial therapy.
KeywordsSurgical site infection Multidrug resistance Surgical debridement Implant retention Antimicrobial therapy
We thank Dr Keyra Martinez, of Edanz Group Ltd., for her editorial assistance during the manuscript preparation.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no potential conflicts of interest.
- 19.Walsh TJ, Standiford HC, Reboli AC, John JF, Mulligan ME, Ribner BS, Montgomerie JZ, Goetz MB, Mayhall CG, Rimland D et al (1993) Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother 37:1334–1342CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Stein A, Bataille JF, Drancourt M, Curvale G, Argenson JN, Groulier P, Raoult D (1998) Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 42:3086–3091PubMedPubMedCentralGoogle Scholar
- 24.Fujino T, Amari Y, Mohri M, Noma M, Yamamoto H (2009) MRSA tricuspid valve infective endocarditis with multiple embolic lung abscesses treated by combination therapy of vancomycin, rifampicin, and sulfamethoxazole/trimethoprim. J Cardiol 53:146–149. doi: 10.1016/j.jjcc.2008.06.007 CrossRefPubMedGoogle Scholar